Palvella Therapeutics PVLA Other Income Expense From Research And Development Tax Credit Receivable
Other Income Expense From Research And Development Tax Credit Receivable at other companies
Other financials
Where this comes from
Reported directly by Palvella Therapeutics in its filing.
Tagged under the XBRL concept pvla:OtherIncomeExpenseFromResearchAndDevelopmentTaxCreditReceivable.
The official record: Palvella Therapeutics’s 10-K, filed March 31, 2026, on SEC EDGAR. View the filing →
Ask your AI about Palvella Therapeutics's other income expense from research and development tax credit receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Palvella Therapeutics's other income expense from research and development tax credit receivable?
- Palvella Therapeutics (PVLA) reported other income expense from research and development tax credit receivable of $0 in Q4 2025.
- How has Palvella Therapeutics's other income expense from research and development tax credit receivable changed year-over-year?
- Palvella Therapeutics's other income expense from research and development tax credit receivable decreased by 100.0% year-over-year, from $494.5K to $0.
- What does other income expense from research and development tax credit receivable mean?
- This represents income recognized from government or third-party tax credits specifically awarded for research and development activities. It serves as a non-operating offset to the high costs associated with clinical-stage drug development. Investors track this to understand the extent to which public policy or tax incentives subsidize the company's innovation pipeline.